Home > Drugs A – Z > Enalapril (By mouth)
  • We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Enalapril (By mouth)

Treats high blood pressure and heart failure. This medicine is an ACE inhibitor.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Enalapril is used alone or together with other medicines to treat high blood pressure (hypertension). High blood pressure adds to the workload of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure. Lowering blood… Read more
Brand names include
Epaned, Vasotec
Drug classes About this
Antihypertensive, Cardiovascular Agent, Renal Protective Agent
Combinations including this drug

What works? Research summarized

Evidence reviews

Enalapril versus losartan for adults with chronic kidney disease: a systematic review and meta-analysis

AIM: Both enalapril and losartan are effective and widely used in patients with chronic kidney disease (CKD). This review aimed to evaluate the benefits of enalapril and losartan in adults with CKD.

Telmisartan versus angiotension-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials

This review found that telmisartan provided superior blood pressure control compared to other angiotensin-converting enzyme inhibitors and had fewer drug-related adverse events. These conclusions are likely to be reliable, but should be interpreted with some caution due to a possibility of publication bias.

Drug Class Review: Direct Renin Inhibitors, Angiotensin Converting Enzyme Inhibitors, and Angiotensin II Receptor Blockers: Final Report [Internet]

The renin-angiotensin system is a complex biologic system between the heart, brain, blood vessels, and kidneys that leads to the production of biologically active agents, including angiotensin I and II and aldosterone, which act together to impact a variety of bodily functions including blood vessel tone, sodium balance, and glomerular filtration pressure. The multiple and varied effects of these agents allows the renin-angiotensin system to play a wide role in the pathology of hypertension, cardiovascular health, and renal function. Our ability to begin to intervene upon the complex cycle of hormone and other biochemical agent production within the renin-angiotensin system began with the advent of the first orally active ACE-I (angiotensin converting enzyme inhibitor), captopril, in 1981. AIIRAs (angiotensin II receptor blockers) were developed as an alternative to ACE-I, and block the interaction between angiotensin II and the angiotensin receptor. Losartan, the first commercially available AIIRA, was approved for clinical use in 1995. The goal of this report is to compare the effectiveness and harms between aliskiren and placebo and between AIIRAs and ACEIs in the treatment of diagnosed coronary heart disease, hypertension, left ventricular dysfunction, heart failure, nondiabetic chronic kidney disease, or diabetic nephropathy.

See all (41)

Summaries for consumers

Comparing ACE Inhibitors and related drugs

How do ACE inhibitors, AIIRAs, and DRIs compare in effectiveness?

Choosing Medicines for High Blood Pressure: A Review of the Research on ACEIs, ARBs, and DRIs

You will learn what research says about three types of medicine for high blood pressure, how well they work, how they compare to each other, and their side effects. This information can help you talk with your doctor as you decide which ACEI, ARB, or DRI is best for you.

Treatment for cardiac problems caused by anthracycline chemotherapy for childhood cancer

Anthracyclines are anti‐cancer drugs that are used in the treatment of different types of childhood cancer. An important adverse effect of anthracyclines is damage to the heart that can lead to asymptomatic (without complaints) or symptomatic (with complaints) cardiac problems during and after cancer treatment. There are several drugs available to treat other types of cardiac problems in adults, but it is not known if these drugs are beneficial in treating cardiac problems caused by anthracyclines in childhood cancer patients and survivors. If a physician is confronted with a childhood cancer patient or survivor with anthracycline‐induced cardiac problems, he or she should be able to make an informed decision to treat this patient based on high‐quality evidence about the beneficial and adverse effects of the treatment options. We searched for and summarised studies that evaluated drugs for treating anthracycline‐induced cardiac problems in childhood cancer patients and survivors.

See all (9)

PubMed Health Blog...

read all...